Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12913186
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus

  2002cited by this paper
• Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors*

  2002cited by this paper
• Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate‐putamen of rats

  2001cited by this paper
• New Aspects of Physiological and Pathophysiological Functions of Adenosine A2A Receptor in Basal Ganglia

  2001cited by this paper
• Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease

  2001cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

  2001cited by this paper
• Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

  2000cited by this paper
• Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.

  2000cited by this paper
• Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.

  2000cited by this paper
• AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

  2000cited by this paper
• Dyskinesias and the subthalamic nucleus.

  2000cited by this paper
• Regulation of AMPA Receptors by Phosphorylation

  2000cited by this paper
• Adenosine A2A receptor facilitation of synaptic transmission in the CA1 area of the rat hippocampus requires protein kinase C but not protein kinase A activation.

  2000cited by this paper
• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  2000cited by this paper
• Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

  1999cited by this paper
• Regulation of ligand-gated ion channels by protein phosphorylation.

  1999cited by this paper
• Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  1998cited by this paper
• Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum.

  1994cited by this paper

• Involvement of Adenosine A2A Receptors in Anxiety‐Like Behaviors in Tetrahydrocannabinol‐Treated Mice

  2026cites this paper
• A2AR antagonists triggered the AMPK/m-TOR autophagic pathway to reverse the calcium-dependent cell damage in 6-OHDA induced model of PD.

  2024cites this paper
• Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents

  2024cites this paper
• Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

  2024cites this paper
• Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

  2024cites this paper
• Efficacy of preladenant in improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis

  2024cites this paper
• Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited

  2023cites this paper
• Dual mechanisms of cholesterol-GPCR interactions that depend on membrane phospholipid composition.

  2023cites this paper
• A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects.

  2023cites this paper
• Non‐lesional treatments for tremor in Parkinson's disease: A systematic review and meta‐analysis

  2023cites this paper
• How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.

  2023cites this paper
• Chemical library design, QSAR modeling and molecular dynamics simulations of naturally occurring coumarins as dual inhibitors of MAO-B and AChE

  2023cites this paper
• Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

  2023cites this paper
• Class A and C GPCR Dimers in Neurodegenerative Diseases

  2022cites this paper
• Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

  2022cites this paper
• Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders

  2022cites this paper
• Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

  2022cites this paper
• Real-world evidence on levodopa dose escalation in patients with Parkinson’s disease treated with istradefylline

  2022influential citation
• Dopamine D2 and Adenosine A2A Receptors Interaction on Ca2+ Current Modulation in a Rodent Model of Parkinsonism

  2022cites this paper
• Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease

  2021cites this paper
• Blockade of adenosine A2A receptors inhibits Tremulous Jaw Movements as well as expression of zif-268 and GAD65 mRNAs in brain motor structures.

  2021cites this paper
• Novel Therapeutic Interventions for Combating Parkinson's Disease and Prospects of Nose-to-Brain Drug Delivery.

  2021cites this paper
• Adenosin A 2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?

  2021cites this paper
• Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer’s Disease and Parkinson’s Disease Treatment (2011–2020)

  2021cites this paper
• Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials

  2021cites this paper
• Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging

  2021cites this paper
• In Vivo Positron Emission Tomography Imaging of Adenosine A2A Receptors

  2020cites this paper
• Adenosine A2A-dopamine D2 receptor-receptor interaction in neurons and astrocytes: Evidence and perspectives.

  2020cites this paper
• Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method

  2020cites this paper
• The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant.

  2020cites this paper
• Conventional and novel pharmacological approaches to treat dopamine-related disorders. Focus on Parkinson's disease and schizophrenia.

  2020cites this paper
• Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review

  2020cites this paper
• Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's Disease.

  2020cites this paper
• C2-substituted quinazolinone derivatives exhibit A1 and/or A2A adenosine receptor affinities in the low micromolar range.

  2020cites this paper
• Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease

  2020cites this paper
• Discovery of novel 1,3,5‐triazine as adenosine A2A receptor antagonist for benefit in Parkinson's disease

  2020cites this paper
• Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration

  2019cites this paper
• Neuroprotection in Parkinson’s disease: facts and hopes

  2019cites this paper
• Modelling alpha-synuclein-based Parkinson's disease and studies with CDNF

  2019cites this paper
• Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor.

  2018cites this paper
• Adenosine role in brain functions: Pathophysiological influence on Parkinson’s disease and other brain disorders

  2018cites this paper
• Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist

  2018cites this paper
• Purinergic modulation of glutamate transmission: An expanding role in stress-linked neuropathology.

  2018cites this paper
• A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.

  2018cites this paper
• Computational Studies Applied to Flavonoids against Alzheimer's and Parkinson's Diseases

  2018cites this paper
• Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists.

  2018cites this paper
• Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia

  2018cites this paper
• Tremorolytic effect of 5′‐chloro‐5′‐deoxy‐(±)‐ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline‐induced model in rats

  2017cites this paper
• Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects

  2017cites this paper
• Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket

  2017cites this paper
• Hypoxic postconditioning attenuates apoptosis via activation of adenosine A2a receptors on dermal microvascular endothelial cells of human flaps.

  2017cites this paper
• Synthesis of 3 H, 2 H4 , and 14 C-MK 3814 (preladenant).

  2017cites this paper
• PET imaging of adenosine A2A receptors

  2017cites this paper
• Promising therapeutic agents for the treatment of Parkinson’s disease

  2016cites this paper
• An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.

  2016cites this paper
• mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias

  2016cites this paper
• Mutation in ADORA1 identified as likely cause of early‐onset parkinsonism and cognitive dysfunction

  2016cites this paper
• Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism.

  2016cites this paper
• Influence of different neuroprotective drugs on dopamine neurotoxicity induced by 3,4-methylenedioxymethamphetamine and MPTP in mice

  2016cites this paper
• Rodent Model as Tools in Ethical Biomedical Research

  2016cites this paper
• In search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptor

  2016cites this paper
• Can coffee consumption lower the risk of Alzheimer’s disease and Parkinson’s disease? A literature review

  2016cites this paper
• Expert Opinion on Biological Therapy

  2016cites this paper
• Radiation Dosimetry of a Novel Adenosine A2A Receptor Radioligand [11C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats

  2016cites this paper
• 1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.

  2015cites this paper
• G-protein-coupled receptor type A heteromers as an emerging therapeutic target

  2015cites this paper
• Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease

  2015cites this paper
• The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

  2015cites this paper
• Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

  2015cites this paper
• Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.

  2015cites this paper
• Beneficial and detrimental role of adenosine signaling in diseases and therapy.

  2015cites this paper
• Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.

  2015cites this paper
• The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.

  2015cites this paper
• Characteristics of Tremorogenesis and Tremorolytic Agents in a Pharmacological Rodent Model of Parkinsonism: Evidence from Behavioral, Neurochemical, and Electrophysiological Studies

  2015cites this paper
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

  2015cites this paper
• The Human Experience with Intravenous Levodopa

  2015cites this paper
• History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents

  2015cites this paper
• Towards next generation adenosine A(2A) receptor antagonists.

  2014cites this paper
• Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.

  2014cites this paper
• Adenosine A2A receptor as a drug discovery target.

  2014cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

  2014cites this paper
• Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.

  2014cites this paper
• Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness.

  2014cites this paper
• Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

  2014influential citation
• JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.

  2014cites this paper
• Emerging therapies for Parkinson's disease: from bench to bedside.

  2014cites this paper
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Moonlighting Proteins and Protein–Protein Interactions as Neurotherapeutic Targets in the G Protein-Coupled Receptor Field

  2014cites this paper
• Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

  2014cites this paper
• Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats

  2014cites this paper
• A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

  2014cites this paper
• Advances in non-dopaminergic treatments for Parkinson's disease

  2014cites this paper
• Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists

  2014cites this paper
• Neural Plasticity and Compensation for Human Brain Damage

  2014cites this paper
• Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.

  2013cites this paper
• Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

  2013cites this paper
• Istradefylline: First Global Approval

  2013cites this paper
• Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?

  2013cites this paper
• Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia.

  2013cites this paper